(firstQuint)Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.

Pneumoniae or E.

Coli.

 In patients with documented ESBL-producing E.

coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.

The primary outcome is clinical response and secondary outcomes are microbiological response and adverse events.

.

 Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.

Pneumoniae or E.

Coli@highlight

In patients with documented ESBL-producing E.

coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.

